Adam Freund
Founder & Chief Executive Officer Arda Therapeutics
Seminars
Wednesday 2nd December 2026
Precision Depletion of Pathogenic Fibroblasts to Treat Fibrosis
9:00 am
- Single-cell mapping across hundreds of human donors nominates surface targets that mark pathogenic fibroblasts in IPF and fibrotic liver
- Cell-depleting biologics directed against these targets (ARDA-101, ARDA-204) eliminate pathogenic fibroblasts and cut collagen production in human IPF lung and fibrotic liver tissue, with rapid, target-dependent depletion in vivo.
- Close target-effector cell distance and low pathogenic-cell burden in fibrosis enable efficient tissue-level killing with a wide therapeutic window.
